CCG
DMK

Capital CS Group’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Capital CS Group’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,344
Closed -$10.9K – 107
2023
Q1 		$10.9K Buy
1,344
+29
+2% +$385 0.01% 59
2022
Q4 		$15.6K Buy
1,315
+204
+18% +$2.33K 0.02% 49
2022
Q3 		$15K Buy
1,111
+30
+3% +$774 0.02% 51
2022
Q2 		$38K Buy
1,081
+74
+7% +$2.31K 0.04% 48
2022
Q1 		$40K Buy
+1,007
New +$43.2K 0.03% 51

Other funds holding DMK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Capital CS Group's DMK Position: Q2 2023 in Review

Capital CS Group sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 1,344 shares — an estimated $10.9K sold.

Capital CS Group first reported a position in DMK in Q1 2022 and held it in 5 quarters. The position peaked at $40K in Q1 2022. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

  • Capital CS Group reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
  • Capital CS Group sold 1,344 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $10.9K.
  • Capital CS Group first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2022 and held it in 5 quarters.
  • Capital CS Group's DMK Pharmaceuticals Corporation Common Stock position peaked at $40K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Capital CS Group's 13F filing for Q2 2023, filed 11 Jul 2023.